Logo image of OCX

ONCOCYTE CORP (OCX) Stock Fundamental Analysis

USA - NASDAQ:OCX - US68235C2061 - Common Stock

3.2 USD
+0.47 (+17.22%)
Last: 6/17/2025, 8:05:27 PM
3.17 USD
-0.03 (-0.94%)
After Hours: 6/17/2025, 8:05:27 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to OCX. OCX was compared to 540 industry peers in the Biotechnology industry. OCX has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, OCX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year OCX has reported negative net income.
OCX had a negative operating cash flow in the past year.
In the past 5 years OCX always reported negative net income.
In the past 5 years OCX always reported negative operating cash flow.
OCX Yearly Net Income VS EBIT VS OCF VS FCFOCX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

The Return On Assets of OCX (-96.52%) is worse than 75.27% of its industry peers.
OCX's Return On Equity of -570.19% is on the low side compared to the rest of the industry. OCX is outperformed by 79.57% of its industry peers.
Industry RankSector Rank
ROA -96.52%
ROE -570.19%
ROIC N/A
ROA(3y)-95.12%
ROA(5y)-75.91%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OCX Yearly ROA, ROE, ROICOCX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 -400

1.3 Margins

With a decent Gross Margin value of 52.56%, OCX is doing good in the industry, outperforming 77.24% of the companies in the same industry.
In the last couple of years the Gross Margin of OCX has declined.
The Profit Margin and Operating Margin are not available for OCX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 52.56%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15.21%
GM growth 5YN/A
OCX Yearly Profit, Operating, Gross MarginsOCX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

More info and screens

3

2. Health

2.1 Basic Checks

OCX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for OCX has been increased compared to 1 year ago.
Compared to 5 years ago, OCX has more shares outstanding
The debt/assets ratio for OCX is higher compared to a year ago.
OCX Yearly Shares OutstandingOCX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
OCX Yearly Total Debt VS Total AssetsOCX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

OCX has an Altman-Z score of -7.51. This is a bad value and indicates that OCX is not financially healthy and even has some risk of bankruptcy.
OCX's Altman-Z score of -7.51 is on the low side compared to the rest of the industry. OCX is outperformed by 69.00% of its industry peers.
OCX has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
OCX has a Debt to Equity ratio of 0.05. This is in the lower half of the industry: OCX underperforms 62.54% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z -7.51
ROIC/WACCN/A
WACC8.92%
OCX Yearly LT Debt VS Equity VS FCFOCX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M

2.3 Liquidity

OCX has a Current Ratio of 3.75. This indicates that OCX is financially healthy and has no problem in meeting its short term obligations.
OCX's Current ratio of 3.75 is in line compared to the rest of the industry. OCX outperforms 43.01% of its industry peers.
OCX has a Quick Ratio of 3.70. This indicates that OCX is financially healthy and has no problem in meeting its short term obligations.
OCX has a Quick ratio of 3.70. This is comparable to the rest of the industry: OCX outperforms 44.27% of its industry peers.
Industry RankSector Rank
Current Ratio 3.75
Quick Ratio 3.7
OCX Yearly Current Assets VS Current LiabilitesOCX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

5

3. Growth

3.1 Past

OCX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 31.19%, which is quite impressive.
Looking at the last year, OCX shows a very strong growth in Revenue. The Revenue has grown by 178.48%.
Measured over the past years, OCX shows a decrease in Revenue. The Revenue has been decreasing by -5.09% on average per year.
EPS 1Y (TTM)31.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.99%
Revenue 1Y (TTM)178.48%
Revenue growth 3Y-5.09%
Revenue growth 5YN/A
Sales Q2Q%1114.77%

3.2 Future

OCX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.86% yearly.
The Revenue is expected to grow by 197.76% on average over the next years. This is a very strong growth
EPS Next Y78.19%
EPS Next 2Y33.55%
EPS Next 3Y21.86%
EPS Next 5YN/A
Revenue Next Year508.91%
Revenue Next 2Y196.65%
Revenue Next 3Y197.76%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
OCX Yearly Revenue VS EstimatesOCX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2M 4M 6M 8M 10M
OCX Yearly EPS VS EstimatesOCX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -2 -4 -6 -8 -10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for OCX. In the last year negative earnings were reported.
Also next year OCX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OCX Price Earnings VS Forward Price EarningsOCX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OCX Per share dataOCX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

A more expensive valuation may be justified as OCX's earnings are expected to grow with 21.86% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.55%
EPS Next 3Y21.86%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for OCX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ONCOCYTE CORP

NASDAQ:OCX (6/17/2025, 8:05:27 PM)

After market: 3.17 -0.03 (-0.94%)

3.2

+0.47 (+17.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2025-05-12/amc
Earnings (Next)08-06 2025-08-06/bmo
Inst Owners56.3%
Inst Owner Change-5.09%
Ins Owners0.97%
Ins Owner Change0%
Market Cap91.52M
Analysts75
Price Target5.53 (72.81%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-178.01%
Min EPS beat(2)-347.17%
Max EPS beat(2)-8.85%
EPS beat(4)1
Avg EPS beat(4)-110.58%
Min EPS beat(4)-347.17%
Max EPS beat(4)36.24%
EPS beat(8)3
Avg EPS beat(8)-69.43%
EPS beat(12)6
Avg EPS beat(12)-56.88%
EPS beat(16)8
Avg EPS beat(16)-44.6%
Revenue beat(2)2
Avg Revenue beat(2)1470.69%
Min Revenue beat(2)1371.29%
Max Revenue beat(2)1570.08%
Revenue beat(4)2
Avg Revenue beat(4)707.66%
Min Revenue beat(4)-67.67%
Max Revenue beat(4)1570.08%
Revenue beat(8)4
Avg Revenue beat(8)355.12%
Revenue beat(12)4
Avg Revenue beat(12)213.18%
Revenue beat(16)5
Avg Revenue beat(16)144.09%
PT rev (1m)20.37%
PT rev (3m)31.31%
EPS NQ rev (1m)0%
EPS NQ rev (3m)26.05%
EPS NY rev (1m)-3.26%
EPS NY rev (3m)38.15%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.17%
Revenue NY rev (1m)106.51%
Revenue NY rev (3m)195.11%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 23.81
P/FCF N/A
P/OCF N/A
P/B 8.96
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.53
EYN/A
EPS(NY)-0.95
Fwd EYN/A
FCF(TTM)-0.82
FCFYN/A
OCF(TTM)-0.8
OCFYN/A
SpS0.13
BVpS0.36
TBVpS-0.15
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -96.52%
ROE -570.19%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 52.56%
FCFM N/A
ROA(3y)-95.12%
ROA(5y)-75.91%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15.21%
GM growth 5YN/A
F-Score4
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 46.45%
Cap/Sales 20.79%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.75
Quick Ratio 3.7
Altman-Z -7.51
F-Score4
WACC8.92%
ROIC/WACCN/A
Cap/Depr(3y)44.29%
Cap/Depr(5y)100.36%
Cap/Sales(3y)166.07%
Cap/Sales(5y)140.26%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)31.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.99%
EPS Next Y78.19%
EPS Next 2Y33.55%
EPS Next 3Y21.86%
EPS Next 5YN/A
Revenue 1Y (TTM)178.48%
Revenue growth 3Y-5.09%
Revenue growth 5YN/A
Sales Q2Q%1114.77%
Revenue Next Year508.91%
Revenue Next 2Y196.65%
Revenue Next 3Y197.76%
Revenue Next 5YN/A
EBIT growth 1Y55.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year38.32%
EBIT Next 3Y10.61%
EBIT Next 5YN/A
FCF growth 1Y47.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y45.8%
OCF growth 3YN/A
OCF growth 5YN/A